title: Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains.
abstract: Modifications of α-synuclein resulting in changes in its conformation are considered to be key pathological events for Lewy body diseases (LBD), which include Parkinson's disease (PD) and dementia with Lewy bodies (DLB). We have previously described a histopathological Unified Staging System for LBD that classifies the spread of α-synuclein phosphorylated at serine 129 (pS129-α-synuclein) from olfactory bulb to brainstem or limbic regions, and finally neocortex. Lewy bodies and Lewy neurites are highly enriched in pS129-α-synuclein. Increased formation of pS129-α-synuclein changes its solubility properties enhancing its tendency to aggregate and disrupt normal function. As in vitro and animal studies have shown that inhibiting formation of pS129-α-synuclein can prevent toxic consequences, this has become one of the therapeutic targets for LBD. However, detailed biochemical descriptions of the changes in pS129-α-synuclein properties in diseased human brains are needed to further our understanding of how these might contribute to molecular pathogenesis. In this study, we used 130 separate brain samples from cingulate cortex (limbic cortex) and 131 from temporal cortex (neocortex) that had been staged according to our Unified Staging System to examine progressive changes in properties of pS129-α-synuclein with the formation of progressively more severe histological Lewy-type pathology. The brain samples from these staged cases had been separated into cytosol-enriched, membrane-enriched (detergent soluble) and insoluble (ureas/SDS soluble) fractions. We also characterized the nature and appearance of higher molecular weight forms of pS129-α-synuclein. The major species was the 16 kD monomeric form; this accumulated with increasing stage with a large increase in Stage IV samples. By comparing two brain regions, we showed higher accumulation of insoluble pS129-α-synuclein in cingulate cortex, where histological deposits occur first, than in temporal cortex in samples with advanced (stage IV) LB pathology.
authors.affiliation: Banner Sun Health Research Institute, Sun City, AZ 85351, USA. douglas.walker@bannerhealth.com
authors.forename: Douglas G
authors.initials: DG
authors.lastname: Walker
authors.forename: Lih-Fen
authors.initials: LF
authors.lastname: Lue
authors.forename: Charles H
authors.initials: CH
authors.lastname: Adler
authors.forename: Holly A
authors.initials: HA
authors.lastname: Shill
authors.forename: John N
authors.initials: JN
authors.lastname: Caviness
authors.forename: Marwan N
authors.initials: MN
authors.lastname: Sabbagh
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Akiyama
authors.forename: Geidy E
authors.initials: GE
authors.lastname: Serrano
authors.forename: Lucia I
authors.initials: LI
authors.lastname: Sue
authors.forename: Thomas G
authors.initials: TG
authors.lastname: Beach
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006179:Gyrus Cinguli / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D020961:Lewy Body Disease / Q000378:metabolism* / Q000473:pathology*; D008297:Male; D010300:Parkinson Disease / Q000378:metabolism / Q000473:pathology; D010766:Phosphorylation / Q000502:physiology; D012694:Serine / Q000378:metabolism; D012995:Solubility; D013702:Temporal Lobe / Q000378:metabolism / Q000473:pathology*; D051844:alpha-Synuclein / Q000378:metabolism*
chemical_list: C497604:SNCA protein, human; D051844:alpha-Synuclein; D012694:Serine